GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » Shiller PE Ratio

Marizyme (Marizyme) Shiller PE Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Marizyme Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Marizyme Shiller PE Ratio Historical Data

The historical data trend for Marizyme's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marizyme Shiller PE Ratio Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Marizyme Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Marizyme's Shiller PE Ratio

For the Biotechnology subindustry, Marizyme's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marizyme's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Marizyme's Shiller PE Ratio falls into.



Marizyme Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Marizyme's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Marizyme's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.05/131.7762*131.7762
=-0.050

Current CPI (Mar. 2024) = 131.7762.

Marizyme Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201109 -2.233 95.727 -3.074
201112 -1.160 95.213 -1.605
201203 -11.861 96.783 -16.150
201206 -0.870 96.819 -1.184
201209 -0.397 97.633 -0.536
201212 0.806 96.871 1.096
201303 -1.296 98.209 -1.739
201306 -0.188 98.518 -0.251
201309 -1.082 98.790 -1.443
201312 0.229 98.326 0.307
201412 -9.367 99.070 -12.459
201512 -8.207 99.792 -10.837
201612 -0.783 101.863 -1.013
201709 0.036 104.136 0.046
201712 -0.578 104.011 -0.732
201803 -0.040 105.290 -0.050
201806 -0.060 106.317 -0.074
201809 -0.070 106.507 -0.087
201812 -0.003 105.998 -0.004
201903 -0.003 107.251 -0.004
201906 -0.010 108.070 -0.012
201909 -0.030 108.329 -0.036
201912 -0.010 108.420 -0.012
202003 -0.020 108.902 -0.024
202006 -0.020 108.767 -0.024
202009 -0.070 109.815 -0.084
202012 -0.090 109.897 -0.108
202103 -0.080 111.754 -0.094
202106 -0.050 114.631 -0.057
202109 -0.050 115.734 -0.057
202112 -0.160 117.630 -0.179
202203 -0.150 121.301 -0.163
202206 -0.170 125.017 -0.179
202209 -0.040 125.227 -0.042
202212 -0.580 125.222 -0.610
202303 -0.060 127.348 -0.062
202306 -0.480 128.729 -0.491
202309 -0.710 129.860 -0.720
202312 -0.160 129.419 -0.163
202403 -0.050 131.776 -0.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Marizyme  (OTCPK:MRZM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Marizyme Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Marizyme's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Marizyme (Marizyme) Business Description

Traded in Other Exchanges
N/A
Address
555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Executives
Braeden Lichti 10 percent owner 650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel director 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart director 5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross officer: Vice President of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov officer: Chief Financial Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel director, officer: Chief Executive Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond officer: Acting VP of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf director 14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk director FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr officer: Executive Vice President 4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl director 448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk officer: Chief Science Officer 1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar officer: Chief Operating Officer 167 CARMELA COURT, JUPITER FL 33478

Marizyme (Marizyme) Headlines

From GuruFocus

Marizyme Signs LOI With Chromocell to Acquire or License Assets

By ACCESSWIRE AccessWire 04-12-2019

Marizyme, Inc., Appoints New Members to its Board of Directors

By PRNewswire PRNewswire 12-15-2018